Great news today on the green light given from the
Post# of 72447
(Total Views: 921)
Posted On: 11/03/2020 12:09:20 AM
Great news today on the green light given from the FDA to initiate human
B-CV19 trials! This is an amazing milestone since the first PR back in February that suggested Brilacidin may be suitable as a coronavirus treatment. The $35k that Leo paid GMU IMO was worth many millions in scientific studies, human trial preparation and design including dosing, competitive and comparative studies, justification to the FDA for advancement to human trials and 3rd party peer review validation. This is one of the best negotiated bargains that I have ever witnessed in my lifetime, second only to Leo’s initial procurement of Brilacidin for $5M in IPIX (CTIX at that time) stock.
I would expect that we will see additional human trial details within the next week or so and would not be surprised if the human trials are initiated within the next 2 weeks. Note that today’s PR used the term “multi-national” so I am excited to see how that is incorporated in the overall 120 person study. It is obvious from the PR that this multi-national component has been approved by the FDA as part of the trial design. As stated by others the actual trials will be very quick and we could very well see interim results yet this calendar year. If these interim results resemble the outstanding GMU lab testing, we will be part owners of an incredibly valuable Brilacidin franchise asset.
B-CV19 trials! This is an amazing milestone since the first PR back in February that suggested Brilacidin may be suitable as a coronavirus treatment. The $35k that Leo paid GMU IMO was worth many millions in scientific studies, human trial preparation and design including dosing, competitive and comparative studies, justification to the FDA for advancement to human trials and 3rd party peer review validation. This is one of the best negotiated bargains that I have ever witnessed in my lifetime, second only to Leo’s initial procurement of Brilacidin for $5M in IPIX (CTIX at that time) stock.
I would expect that we will see additional human trial details within the next week or so and would not be surprised if the human trials are initiated within the next 2 weeks. Note that today’s PR used the term “multi-national” so I am excited to see how that is incorporated in the overall 120 person study. It is obvious from the PR that this multi-national component has been approved by the FDA as part of the trial design. As stated by others the actual trials will be very quick and we could very well see interim results yet this calendar year. If these interim results resemble the outstanding GMU lab testing, we will be part owners of an incredibly valuable Brilacidin franchise asset.
(19)
(0)